ACOR - Acorda Oversold: Runway To Positive Cash Flow
Acorda Therapeutics (ACOR) has had a difficult year with the genericization of their AMPYRA asset coming from a court decision in September 2018. The company has lost over half of its equity value YTD and investors have been continually selling shares even amidst a strong bull market.
However, I contend that ACOR represents an interesting positive return opportunity as the market becomes more rational over the coming quarters as company fundamentals demonstrate significant equity value upside in the company's remaining net assets.
Fundamentally Oversold?
ACOR's current market capitalization of ~$330 million is too